Marshall Wace, LLP Provention Bio, Inc. Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$6.7 - $24.21 $499,150 - $1.8 Million	74,500 New	74,500 $1.8 Million
Q3 2022 Nov 14, 2022	BUY	$3.43 - $5.62 $218,069 - $357,302	63,577 Added 371.62%	80,685 $362,000
Q2 2022 Aug 15, 2022	BUY	$3.65 - $7.3 $62,444 - $124,888	17,108 New	17,108 $69,000
Q2 2021 Aug 13, 2021	SELL	$6.71 - $11.04 $163,831 - $269,552	-24,416 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$10.12 - $19.45 $247,089 - $474,891	24,416 New	24,416 $256,000
Q4 2020 Feb 16, 2021	SELL	$11.79 - $18.94 $548,765 - $881,562	-46,545 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$10.34 - $15.2 $1.99 Million - $2.93 Million	-192,928 Reduced 80.56%	46,545 $598,000
Q2 2020 Aug 13, 2020	BUY	$7.81 - $17.0 $1.87 Million - $4.07 Million	239,473 New	239,473 $3.38 Million

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.